Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed Aug 9, 2022 · 10-Q · 40 days after period end · 0001731122-22-001301
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Net Income | -$12.37M | -$10.18M | -$6.49M | -$6.52M |
| EPS Diluted | — | -$0.14 | -$0.11 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end
